Taking stock of the drug industry, from the lab to the medicine chestSeptember 13, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer José A. Alvarado Jr. for STAT STAT+ | A new drug offers a rare option for brain cancer treatment — and inspires hopes for more FDA-approved last month, the drug from Servier is one of the first major brain tumor breakthroughs in decades, say neuro-oncologists. By Andrew Joseph Opinion: Compounded semaglutide is an ill-defined public health crisis A cardiologist writes that he's seeing vulnerable patients turn to questionable yet convenient compounded semaglutide solutions online. By Vishal Khetpal STAT+ | FDA approves Roche's injectable version of blockbuster multiple sclerosis drug Patients will be able to get a 10-minute injection, instead of an hours-long infusion. Novartis already has its own injectable MS drug, Kesimpta. By Jonathan Wosen Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and weight loss drugs for kids. By Adam Feuerstein, Allison DeAngelis, and Elaine Chen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments